CancerX shared on LinkedIn:
“GOOD NEWS CancerX Accelerator
We’re excited to share that applications for the CancerX Accelerator 2027 Cohort have been extended to November 30, 2026!
We know the journey for oncology founders isn’t easy. Feedback takes time, sales cycles can stretch to 18 months, and reaching the right clinicians, health systems, and payers can feel like an uphill climb.
That’s exactly the challenge the CancerX Accelerator was built to solve.
This year, our CancerX champions, including Advocate Health, Moffitt Cancer Center, AstraZeneca, Johnson and Johnson, Rush University Medical Center, Novartis, Elevance Health, Oncology Ventures, Flare Capital Partners, and many more, have come together around three priorities in cancer care:
- Increasing access to clinical trials and research
- Increasing access to excellent cancer care, everywhere
- Increasing access to smarter care operations
If your solution can help change what cancer care looks like, we’d love to hear from you.
New deadline: November 30, 2026
Apply now.
Be part of this moment in cancer innovation.”
Other articles about CancerX on OncoDaily.